摘要
目的:通过网络药理学和分子对接探讨血人参(Indigofera stachyodes Lindl.)治疗肺痈的可行性和潜在机制。方法:将血人参药材用水煎煮浓缩为1.0 g/ml的药液,大鼠随机分为空白血浆组、给药后1 h采血组、给药后2 h采血组、给药后3 h采血组4组(每组8只),连续灌胃一周,分别采血,制备血浆,运用液质联用技术对四组血浆的化学成分进行鉴定,然后用Venny 2.1作Venn图进行筛选;通过TCMSP、SymMap、SwissTargetPrediction、SEA等数据库筛选血人参成分及靶点。通过GeneCards、OMIM数据库筛选肺痈的疾病靶点。通过R语言获取药物疾病交集靶点,通过蛋白互作和PPI分析获得关键靶点,并利用关键靶点进行KEGG、GO富集分析以及分子对接。结果:通过HPLC-MS分析并排除TCMSP中搜索不到的成分,获得Hypoxanthine等11个血人参活性化合物,337个靶点,2243个肺痈的疾病靶点,“血人参–肺痈”交集靶点113个,关键基因15个,KEGG富集分析结果显示,血人参主要通过调控VEGF信号通路、Rap1信号通路、TNF信号通路等参与肺痈的调节机制。分子对接结果显示,EGFR与Fisetin的亲和力最高;SRC与Fisetin的亲和力最高;PLCG1与2-Naphthylamine的亲和力最高;PIK3R1与Fisetin的亲和力最高;PTK2与Fisetin的亲和力最高。结论:血人参的活性成分可能通过影响免疫反应、炎症反应和细胞凋亡等生物学过程,发挥治疗肺痈的作用。Objective: To explore the feasibility and potential mechanisms of the treatment of lung abscess with Indigofera stachyodes Lindl. through network pharmacology and molecular docking. Methods: The medicinal material of I. stachyodes Lindl. was decocted in water and concentrated into a medicinal solution of 1.0 g/ml. Rats were randomly divided into four groups, including the blank plasma group, the blood collection group at 1 h after administration, the blood collection group at 2 h after administration, and the blood collection group at 3 h after adminis
出处
《药物资讯》
2024年第6期482-492,共11页
Pharmacy Information
